Mesothelioma is a type of late‐onset cancer that develops in cells covering the outer surface
of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining …

Simple Summary Many clinical trials have investigated the role of Immune Checkpoint
Inhibitors (ICIs) in pleural mesothelioma (PM), with contrasting results. We performed a …

We assessed the murine Stimulator of Interferon Genes (STING) agonist, DMXAA, for anti-
mesothelioma potential using the AE17-sOVA model that expresses ovalbumin (OVA) as a …

Objectives Malignant pleural mesothelioma (MPM) is an aggressive disease with grim
prognosis due to lack of effective treatment options. Disease prediction in association with …

In this commentary, using existing clinical trial data and FDA approvals we propose that
there is currently a critical need for an appropriate balancing between the financial impact of …

Introduction Despite increased attention on immunotherapy, primarily immune checkpoint
blockade, as a therapeutic approach for mesothelioma (MMe), its efficacy and tolerability …

Malignant mesothelioma is a rare and aggressive cancer that develops in the thin layer
surrounding the mesothelium and is mainly caused by asbestos exposure. Despite …

Programmed cell death protein-1 (PD1), PD1 ligand 1 (PD-L1), and human leukocyte
antigen (HLA) class I molecule play pivotal roles in T cell-induced anti-tumor immunity; …

ABSTRACT Introduction Malignant mesothelioma (MMe) is an aggressive rare cancer of the
mesothelium, associated with asbestos exposure. MMe is currently an incurable disease at …

Malignant pleural mesothelioma (MPM) is a fatal disease of respiratory system. Despite the
availability of invasive biomarkers with promising results, there are still significant diagnostic …